RBC Capital analyst Maurice Choy maintained a Hold rating on Capital Power (CPX – Research Report) on October 3 and set a price target of C$44.00. The company’s shares closed yesterday at C$50.57.
Over the years, Celator has developed a unique, proprietary drug combination platform technology: CombiPlex. Combination therapy is a powerful and effective therapeutic regimen in the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results